Navigation Links
La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial

Data Support Ability of Higher Doses to Further Reduce Antibodies to Double-Stranded DNA

SAN DIEGO, March 08, 2007 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company today announced positive interim antibody results from its ongoing double-blind, placebo-controlled randomized Phase 3 trial of Riquent(R) (abetimus sodium), its drug candidate for systemic lupus erythematosus ("lupus" or "SLE"). Analyses of interim antibody data indicate that patients treated with 900 mg or 300 mg per week doses of Riquent had greater reductions in antibodies to double-stranded DNA (dsDNA) than patients treated with 100 mg per week or placebo. The results showed a significant dose response when comparing all Riquent-treated patients to placebo-treated patients (p < 0.0001), and each Riquent dose group to the placebo dose group (p < 0.0015 for 100 mg, p < 0.0001 for 300 mg and 900 mg).

"We are very excited by these results. The higher the dose, the greater the reduction in antibodies to dsDNA, and the relative magnitude of these reductions is greater than we have seen in previous studies, which used lower doses of Riquent. Higher doses also appear to result in a larger percentage of patients having greater and more consistent antibody reductions over time," said Deirdre Y. Gillespie, M.D., President and CEO of La Jolla Pharmaceutical Company. "In addition, preliminary assessment of the data indicates that Riquent is being as well tolerated at all doses in the ongoing Phase 3 study as in our previous studies. We believe that the greater reductions in antibodies to dsDNA observed with these higher doses of Riquent imply a greater probability of obtaining positive clinical results from the Phase 3 trial."

"These data definitely show an increased biological effect. This will improve the likelihood of detecting clinical effects of the treatment," said Joan Merrill, M.D. of the Oklahoma Medical Research Foundation. "
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/11/2014)... July 11, 2014 On ... down 0.52%, the Dow Jones Industrial Average finished the day ... 1,964.68, down 0.41%. The losses were broad based as eight ... S&P 500 Health Care Sector Index ended the day at ... the last one month. Investor-Edge has initiated coverage on the ...
(Date:7/11/2014)... 11, 2014  Veran Medical Technologies, a ... the positive, cost-effective final results for the ... The SPiNPerc endobronchial percutaneous biopsy study results ... to biopsy when a traditional bronchoscopic method ... experience positive financial outcomes when more can ...
(Date:7/10/2014)...  Major advances in radiation therapy and radiosurgery ... in a three-day Oncology Summit taking place in ...  Renowned national and international cancer experts from seven countries ... knowledge on modern technologies making treatment for cancer ... The Summit will address a wide spectrum ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Veran Medical Publishes Lung Cancer Patient Management Study 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... April 7, 2011 Cempra Pharmaceuticals Inc. today announced ... will present at two upcoming CHI conferences.  Dr. Fernandes ... Molecule Approaches Conference at 5 p.m. PDT, April ... Diego.  Her presentation is entitled "Macrolides as a New ...
... YORK, April 7, 2011 Reportlinker.com announces that a ... Global Market for Medical Devices, 2nd ... The medical device market is vast -- everything from ... be classified as a type of medical device -- ...
Cached Medicine Technology:Cempra Pharmaceuticals to Present at Two Upcoming Cambridge Healthtech Institute (CHI) Conferences 2Reportlinker Adds Global Market for Medical Devices, 2nd Edition 2Reportlinker Adds Global Market for Medical Devices, 2nd Edition 3Reportlinker Adds Global Market for Medical Devices, 2nd Edition 4Reportlinker Adds Global Market for Medical Devices, 2nd Edition 5
(Date:7/12/2014)... (PRWEB) July 12, 2014 “Critical ... - New and Late-Stage Four-Factor PCCs and Recombinant ... of the critical care market in the US, ... The report provides an estimation of market size ... It covers critical care indications that are being ...
(Date:7/12/2014)... 12, 2014 Utah Valley Entrepreneurial Forum ... with awards being bestowed to companies in revenue, and ... entrepreneur community with recognition for new ideas as well ... incoming revenue. , 25 Under 5 highlights outstanding Utah ... are under 5 years old. Award recipients were recognized ...
(Date:7/12/2014)... July 12, 2014 Praeclarus Press ... Simple as a valuable new resource for women in ... of American women work away from their children. Today’s ... the benefits of breastfeeding, but often feel unsupported when ... their babies. With its evidence-based insights, and written by ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 ... score of 4.1 out of 5. This above-average ... have been underpinning buyer negotiation power over the ... analyst Anna Son, “during the period, surging demand ... costs associated with new product development, have placed ...
(Date:7/12/2014)... 2014 Ladies, it doesn't matter what your ... who are looking for an affordable gown can visit ... dresses) to get their dream items. Recently, the company has ... gowns . Along with that, it is also providing great ... special offer; the deadline of this promotion is July 29, ...
Breaking Medicine News(10 mins):Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2
... Fi-Med,Management, Inc. announced last week the acquisition of ... Utah and southern California., (Logo: http://www.newscom.com/cgi-bin/prnh/20080130/AQW173 ... 2007, comes at the confluence of,two goals: for ... on board for their clients in an IT-savvy ...
... Occupational Safety and Health Administration (OSHA) announced,today in ... for,persons to serve on the National Advisory Committee ... under section 7(a) of the,Occupational Safety and Health ... Labor,and the Secretary of Health and Human Services ...
... IDC on top for the 4th time., ... Ltd.) (TSX: IDL), the global leader in high-quality, ... third consecutive,quarter it received highest ranking in user ... vendors in the January 2008,Intelligence Report by MD ...
... , , WEDNESDAY, Jan. 30 (HealthDay News) -- An operation ... of a major heart artery has a lower ... according to a major new study. , "There have ... of which showed perioperative benefits with EVAR [endovascular aneurysm ...
... Financial Highlights and Potential Milestones include:, - ... Application submission in Q1, - Pixantrone phase ... - Brostallicin phase II interim results SEATTLE, Jan. ... announced today that with the return of CTI,to a ...
... MYL ),today announced that in accordance with its 2.139 ... dividend of $15.53,per share (based on the annual dividend rate ... the time period from the date of,issuance to February 15, ... of record as of February 1, 2008., Mylan Inc. ...
Cached Medicine News:Health News:OSHA Seeking Nominations for National Advisory Committee on Occupational Safety and Health 2Health News:IDC Digital radiography systems Ranked #1 for third consecutive quarter 2Health News:Minimally Invasive Surgery Fixes Aneurysms 2Health News:Minimally Invasive Surgery Fixes Aneurysms 3Health News:Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009 2Health News:Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009 3Health News:Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009 4Health News:Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009 5
... high-power, apochromatically corrected objectives ... the most exacting demands ... are suitable for visual ... 25 mm and feature ...
... transmission rate in the ultraviolet down to ... fluor-3; these objectives have,improved signal to noise ... Numerical Apertures for significantly sharper and brighter ... and a 2mm working distance to allow ...
... Featuring longer working distances with high ... to correct all optical aberrations throughout the ... centre to edges across the entire 25mm ... image flatness and colour reproduction, plus resolving ...
... an extra-high transmission rate, especially in ... to the CFI plan Achromat series, ... observation and photomicrography. Because of ... as multipurpose objectives for brightfield, fluorescence, ...
Medicine Products: